Literature DB >> 26703429

Uric acid in metabolic syndrome: From an innocent bystander to a central player.

Mehmet Kanbay1, Thomas Jensen2, Yalcin Solak3, Myphuong Le2, Carlos Roncal-Jimenez2, Chris Rivard2, Miguel A Lanaspa2, Takahiko Nakagawa4, Richard J Johnson5.   

Abstract

Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease. Several experimental and clinical studies support a role for uric acid as a contributory causal factor in these conditions. Here we discuss some of the major mechanisms linking uric acid to metabolic and cardiovascular diseases. At this time the key to understanding the importance of uric acid in these diseases will be the conduct of large clinical trials in which the effect of lowering uric acid on hard clinical outcomes is assessed. Elevated uric acid may turn out to be one of the more important remediable risk factors for metabolic and cardiovascular diseases.
Copyright © 2015 European Federation of Internal Medicine. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Diabetes mellitus; Hypertension; Kidney disease; Metabolic syndrome; Uric acid

Mesh:

Substances:

Year:  2015        PMID: 26703429      PMCID: PMC4826346          DOI: 10.1016/j.ejim.2015.11.026

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  108 in total

1.  Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation.

Authors:  Kazuko Masuo; Hideki Kawaguchi; Hiroshi Mikami; Toshio Ogihara; Michael L Tuck
Journal:  Hypertension       Date:  2003-09-02       Impact factor: 10.190

2.  Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress.

Authors:  Christine Gersch; Sergiu P Palii; Witcha Imaram; Kyung Mee Kim; S Ananth Karumanchi; Alexander Angerhofer; Richard J Johnson; George N Henderson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-02       Impact factor: 1.381

3.  Genotype-based changes in serum uric acid affect blood pressure.

Authors:  Afshin Parsa; Eric Brown; Matthew R Weir; Jeffrey C Fink; Alan R Shuldiner; Braxton D Mitchell; Patrick F McArdle
Journal:  Kidney Int       Date:  2011-12-21       Impact factor: 10.612

4.  Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells.

Authors:  Hung-hsing Chao; Ju-chi Liu; Jia-wei Lin; Cheng-hsien Chen; Chieh-hsi Wu; Tzu-hurng Cheng
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

5.  Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.

Authors:  Kazuhide Ogino; Masahiko Kato; Yoshiyuki Furuse; Yoshiharu Kinugasa; Katsunori Ishida; Shuichi Osaki; Toru Kinugawa; Osamu Igawa; Ichiro Hisatome; Chiaki Shigemasa; Stefan D Anker; Wolfram Doehner
Journal:  Circ Heart Fail       Date:  2009-11-20       Impact factor: 8.790

6.  Thiazide diuretics exacerbate fructose-induced metabolic syndrome.

Authors:  Sirirat Reungjui; Carlos A Roncal; Wei Mu; Titte R Srinivas; Dhavee Sirivongs; Richard J Johnson; Takahiko Nakagawa
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

7.  Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice.

Authors:  Stéphane Cook; Olivier Hugli; Marc Egli; Peter Vollenweider; Rémy Burcelin; Pascal Nicod; Bernard Thorens; Urs Scherrer
Journal:  Swiss Med Wkly       Date:  2003-06-28       Impact factor: 2.193

Review 8.  Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology.

Authors:  Richard J Johnson; Peter Stenvinkel; Sandra L Martin; Alkesh Jani; Laura Gabriela Sánchez-Lozada; James O Hill; Miguel A Lanaspa
Journal:  Obesity (Silver Spring)       Date:  2013-04       Impact factor: 5.002

9.  Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome.

Authors:  Miguel A Lanaspa; Takuji Ishimoto; Nanxing Li; Christina Cicerchi; David J Orlicky; Philip Ruzycki; Philip Ruzicky; Christopher Rivard; Shinichiro Inaba; Carlos A Roncal-Jimenez; Elise S Bales; Christine P Diggle; Aruna Asipu; J Mark Petrash; Tomoki Kosugi; Shoichi Maruyama; Laura G Sanchez-Lozada; James L McManaman; David T Bonthron; Yuri Y Sautin; Richard J Johnson
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.

Authors:  Hyun Ah Kim; Young-Il Seo; Yeong W Song
Journal:  J Korean Med Sci       Date:  2014-07-30       Impact factor: 2.153

View more
  95 in total

Review 1.  Dietary and commercialized fructose: Sweet or sour?

Authors:  Aslihan Yerlikaya; Tuncay Dagel; Christopher King; Masanari Kuwabara; Miguel A Lanaspa; Ana Andres-Hernando; Adrian Covic; Jacek Manitius; Alan A Sag; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2017-02-16       Impact factor: 2.370

2.  Positive association between serum uric acid and bone mineral density in Chinese type 2 diabetes mellitus stratified by gender and BMI.

Authors:  Mingxin Xu; Junlei Su; Jie Hao; Ni Zhong; Zhiyin Zhang; Ran Cui; Feng Li; Chunjun Sheng; Ge Zhang; Hui Sheng; Shen Qu
Journal:  J Bone Miner Metab       Date:  2017-11-09       Impact factor: 2.626

Review 3.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Diabetologia       Date:  2016-11-22       Impact factor: 10.122

4.  A Powerful Approach to Estimating Annotation-Stratified Genetic Covariance via GWAS Summary Statistics.

Authors:  Qiongshi Lu; Boyang Li; Derek Ou; Margret Erlendsdottir; Ryan L Powles; Tony Jiang; Yiming Hu; David Chang; Chentian Jin; Wei Dai; Qidu He; Zefeng Liu; Shubhabrata Mukherjee; Paul K Crane; Hongyu Zhao
Journal:  Am J Hum Genet       Date:  2017-12-07       Impact factor: 11.025

5.  Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Di Zhao; Hui Liu; Pingshuan Dong
Journal:  J Hum Hypertens       Date:  2018-11-15       Impact factor: 3.012

Review 6.  The role of uric acid in mineral bone disorders in chronic kidney disease.

Authors:  Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

7.  Assessment of cardiovascular risk profile based on measurement of tophus volume in patients with gout.

Authors:  Kyung-Ann Lee; Se-Ri Ryu; Seong-Jun Park; Hae-Rim Kim; Sang-Heon Lee
Journal:  Clin Rheumatol       Date:  2017-12-29       Impact factor: 2.980

8.  Ketohexokinase C blockade ameliorates fructose-induced metabolic dysfunction in fructose-sensitive mice.

Authors:  Miguel A Lanaspa; Ana Andres-Hernando; David J Orlicky; Christina Cicerchi; Cholsoon Jang; Nanxing Li; Tamara Milagres; Masanari Kuwabara; Michael F Wempe; Joshua D Rabinowitz; Richard J Johnson; Dean R Tolan
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

Review 9.  Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.

Authors:  Samir G Mallat; Sahar Al Kattar; Bassem Y Tanios; Abdo Jurjus
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

Review 10.  The tubular hypothesis of nephron filtration and diabetic kidney disease.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Nat Rev Nephrol       Date:  2020-03-09       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.